Results 11 to 20 of about 169,996 (318)

Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.

JAMA cardiology, 2022
Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute coronary syndrome (ACS).
Hirotoshi Watanabe, T. Morimoto, M. Natsuaki, Ko Yamamoto, Y. Obayashi, M. Ogita, S. Suwa, T. Isawa, T. Domei, K. Yamaji, Shojiro Tatsushima, Hiroki Watanabe, M. Ohya, H. Tokuyama, T. Tada, H. Sakamoto, Hiroyoshi Mori, Hiroshi Suzuki, Tenjin Nishikura, K. Wakabayashi, K. Hibi, M. Abe, K. Kawai, K. Nakao, K. Ando, K. Tanabe, Y. Ikari, Y. Morino, K. Kadota, Y. Furukawa, Y. Nakagawa, T. Kimura   +31 more
semanticscholar   +1 more source

Mixture of clopidogrel bisulfate and magnesium oxide tablets reduces clopidogrel dose administered through a feeding tube

Journal of Pharmaceutical Health Care and Sciences, 2021
Background In clinical practice, a mixed suspension of clopidogrel bisulfate and magnesium oxide (MgO) tablets is administered frequently via a feeding tube.
Manahito Aoki, Midori Naya, Shiho Arima, Kaori Shinohara, Masahiro Kato, Kiyoshi Shibuya, Masaki Ohtawa, Tohru Nagamitsu, Katsuya Otori   +8 more
doaj   +1 more source

Effectiveness and Safety of Reduced-Dose Prasugrel in an East Asian Population: PRASFIT-ACS Emulation Using National Health Insurance Claims Data. [PDF]

Clin Pharmacol Ther
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Huang LW, Wu YJ, Lin FJ, Wu CC, Huang HY, Wang CC, Li X.   +6 more
europepmc   +2 more sources

Ticlopidine and Clopidogrel [PDF]

Circulation, 1999
Abstract —The thienopyridines ticlopidine and clopidogrel are inhibitors of platelet function in vivo. Their mode of action has not been defined, but it appears that they require conversion to as yet unidentified metabolites that are noncompetitive antagonists of the platelet ADP receptor. Inhibition
Martin J. Quinn, Desmond J. Fitzgerald
openaire   +2 more sources

Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study

Circulation, 2022
Background: Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Extended Antiplatelet Monotherapy ...
Jeehoon Kang, Kyung-Woo Park, H. Lee, D. Hwang, Han-Mo Yang, S. Rha, J. Bae, N. Lee, S. Hur, J. Han, E. Shin, B. Koo, Hyo‐Soo Kim   +12 more
semanticscholar   +1 more source

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction

Frontiers in Pharmacology, 2021
Objective: To explore the treatment effect of statins used together with clopidogrel on cerebral infarction (CI).Methods: One hundred and thirty non-clopidogrel resistant patients were divided into a dynamic clopidogrel resistant (DCR) group and a ...
Hong Ting Shi, Yong Yuan Chen, Xiao Ying Li, Jian Hua Luo, Guang Hong Zhong, Jia Jia Hu, Min Zhang, Bo Rong Zhou   +7 more
doaj   +1 more source

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.

New England Journal of Medicine, 2021
BACKGROUND Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.
Yongjun Wang, Xia Meng, Anxin Wang, Xuewei Xie, Yuesong Pan, S. Johnston, Hao Li, P. Bath, Q. Dong, Anding Xu, J. Jing, Jinxi Lin, Siying Niu, Yilong Wang, Xingquan Zhao, Zixiao Li, Yong Jiang, Wei Li, Liping Liu, Jie Xu, L. Chang, Lihua Wang, Xianbo Zhuang, Jinguo Zhao, Yefang Feng, Honghao Man, Guozhong Li, Baojun Wang   +27 more
semanticscholar   +1 more source

Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease

Platelets, 2023
Clopidogrel combined with aspirin is widely used in coronary artery disease (CAD) patients, while some patients exhibit high platelet activity when receiving the combined treatment. Current environmental and genetic factors could only explain part of the
Xiaolei Hu, Mupeng Li, He Li, Peiyuan Song, Yanjiao Zhang, Gan Zhou, Jie Tang, Liming Peng, Qilin Ma, Xiaoping Chen   +9 more
doaj   +1 more source

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China

Frontiers in Cardiovascular Medicine, 2023
BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo, Yao Lu, Fei Guo, Aihua Wu, Yuesong Weng   +4 more
doaj   +1 more source

Clopidogrel (Plavix) [PDF]

American Journal of Neuroradiology, 2011
Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with ...
J, Comin, D, Kallmes
openaire   +2 more sources